Paper
8 January 2024 Anti-cytokine strategies targeting CAR-T cell therapy-induced cytokine release syndrome
Xiaotong Liu
Author Affiliations +
Proceedings Volume 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023); 1292430 (2024) https://doi.org/10.1117/12.3012927
Event: 3rd International Conference on Biological Engineering and Medical Science (ICBioMed2023), 2023, ONLINE, United Kingdom
Abstract
CAR-T cell therapy is a highly promising therapy, recently developed to treat haematological malignancies. However, many limitations including immunosuppressive microenvironment, cytokine-induced toxicities, neurotoxicity, antigen escape, cell trafficking, and tumour infiltration are still in the way of safely applying this therapy. IL-6 and IL-1 are key players in the cytokine storm, produced by bystander immune cells and CAR-T cells. The secreted cytokines and chemokines can lead to cytokine release syndrome (CRS) and ways to overcome this are being studied. In this review, recent findings on anti-cytokine treatments using monoclonal antibodies or recombinant proteins targeting CAR-T cellinduced cytokine storm will be discussed.
(2024) Published by SPIE. Downloading of the abstract is permitted for personal use only.
Xiaotong Liu "Anti-cytokine strategies targeting CAR-T cell therapy-induced cytokine release syndrome", Proc. SPIE 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023), 1292430 (8 January 2024); https://doi.org/10.1117/12.3012927
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Chromium

Monoclonal antibodies

Toxicity

Cancer

Diseases and disorders

Clinical trials

Proteins

Back to Top